KDR and non-small cell lung carcinoma: Herein, we describe the results of the Phase I trial of the novel triplet of avelumab (anti‐PD‐L1 immunotherapy), axitinib (anti‐VEGFR), and palbociclib (CDK4/6 inhibitor) in NSCLC, which showed activity and tolerability in NSCLC.